Canagliflozin → Diabetic foot — Audit-grade candidate (class scan)

← All findings ⬇ Download signed audit packet

Ledger entry · candidate

Canagliflozin → Diabetic foot — Audit-grade candidate (class scan)

Drug: canagliflozin · AE: Diabetic foot

Discovered via class scan of SGLT2 inhibitors. PRR = 164.03, n = 749 cases.

Disproportionality

PRR: 164.026466976581
Yates χ²: n/a
Cases (case-drug + AE): n = 749
Verdict: PASSES_ALL_GATES — PRR=164.03 (95% CI 151.73–177.32), n=749 cases; flagged for clinical expert review, NOT for external escalation without manual verification

Top reactions in cohort

MedDRA PT	n
No reactions surfaced in cohort.

Source: openFDA FAERS, Caliper Engine v0. Pre-registration sha1 locked at submission time; ledger entry signed with platform Ed25519 key.

Independent Verification & Validation

Every finding includes an in-engine adversary review at no cost. For findings you plan to cite in a regulatory submission, scientific publication, or board-grade decision, we offer an additional layer of independent, audit-grade verification — reviewed by an externally-trained system that has never seen your data, your training corpus, or our hardware, and cryptographically signed.

Reference: 09949374f20be5a69e88f600aad72319636b9152